[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2177240T3 - Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas. - Google Patents

Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas.

Info

Publication number
ES2177240T3
ES2177240T3 ES99906067T ES99906067T ES2177240T3 ES 2177240 T3 ES2177240 T3 ES 2177240T3 ES 99906067 T ES99906067 T ES 99906067T ES 99906067 T ES99906067 T ES 99906067T ES 2177240 T3 ES2177240 T3 ES 2177240T3
Authority
ES
Spain
Prior art keywords
porphyria
enzyme
treatment
pbgd
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99906067T
Other languages
English (en)
Inventor
Jens Fogh
Par Gellerfors
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HemeBiotech AS
Original Assignee
HemeBiotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HemeBiotech AS filed Critical HemeBiotech AS
Application granted granted Critical
Publication of ES2177240T3 publication Critical patent/ES2177240T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

El uso de una cantidad efectiva de un catalizador que es una enzima perteneciente a la ruta de biosíntesis del hemo o una parte enzimáticamente equivalente o su análogo, junto con un portador farmacéuticamente aceptable para la preparación de una composición farmacéutica para el tratamiento o profilaxis de una enfermedad causada por una deficiencia, en un sujeto, de una enzima perteneciente a la ruta de biosíntesis del hemo.
ES99906067T 1998-01-27 1999-01-27 Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas. Expired - Lifetime ES2177240T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK11298 1998-01-27
DKPA199801748 1998-12-30

Publications (1)

Publication Number Publication Date
ES2177240T3 true ES2177240T3 (es) 2002-12-01

Family

ID=26063333

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99906067T Expired - Lifetime ES2177240T3 (es) 1998-01-27 1999-01-27 Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas.

Country Status (11)

Country Link
EP (1) EP1049487B1 (es)
JP (1) JP2002501032A (es)
AT (1) ATE217799T1 (es)
AU (1) AU750143B2 (es)
CA (1) CA2319096C (es)
DE (1) DE69901536T2 (es)
DK (1) DK1049487T3 (es)
ES (1) ES2177240T3 (es)
NO (1) NO327241B1 (es)
PT (1) PT1049487E (es)
WO (1) WO1999037325A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
ATE315084T1 (de) * 1999-07-27 2006-02-15 Zymenex As Herstellung von rhpbgd
NZ589037A (en) 2004-01-30 2011-10-28 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
PL2100898T3 (pl) 2006-04-04 2019-11-29 Chiesi Farm Spa Sposób zatężania polipeptydu
ES2507540T3 (es) 2008-09-29 2014-10-15 Uniqure Ip B.V. Terapia génica de porfobilinógeno deaminasa
WO2013009686A2 (en) 2011-07-08 2013-01-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
AU2013216920B2 (en) 2012-02-07 2016-09-22 Global Bio Therapeutics, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
ES2768261T3 (es) 2013-01-09 2020-06-22 Shire Human Genetic Therapies Métodos para la purificación se arilsulfatasa A
DK3030163T3 (da) 2013-08-08 2019-07-01 Global Bio Therapeutics Inc Klemmeindretning til minimalt invasive procedurer
WO2017201346A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
US11390854B2 (en) 2017-05-09 2022-07-19 Fundacion Para La Investigacion Medica Aplicada Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657345B2 (ja) * 1992-04-17 1997-09-24 新日本製鐵株式会社 医療用診断装置および疾患判断方法

Also Published As

Publication number Publication date
ATE217799T1 (de) 2002-06-15
CA2319096C (en) 2007-07-03
DE69901536D1 (de) 2002-06-27
CA2319096A1 (en) 1999-07-29
JP2002501032A (ja) 2002-01-15
EP1049487B1 (en) 2002-05-22
NO327241B1 (no) 2009-05-18
PT1049487E (pt) 2002-10-31
EP1049487A2 (en) 2000-11-08
AU2609799A (en) 1999-08-09
NO20003830L (no) 2000-09-27
AU750143B2 (en) 2002-07-11
WO1999037325A3 (en) 1999-09-30
DK1049487T3 (da) 2002-09-16
NO20003830D0 (no) 2000-07-26
WO1999037325A2 (en) 1999-07-29
DE69901536T2 (de) 2003-01-16

Similar Documents

Publication Publication Date Title
ES2177240T3 (es) Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas.
Mitsumoto et al. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin
ES2496491T3 (es) Procedimientos nuevos y medicamento destinado al tratamiento de enfermedades infecciosas que implican biopelículas microbianas
Scharffetter et al. Synergistic effect of tumor necrosis factor-α and interferon-γ on collagen synthesis of human skin fibroblasts in vitro
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
BR9809921A (pt) Método para admistração de composição de microorganismos viáveis para aves domésticas
DE60030970D1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
RU2010150428A (ru) Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения
MXPA02007059A (es) Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado.
US20170112751A1 (en) Cosmetic composition
Noh et al. Characterization of mycoplasma arginine deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis
ATE337712T1 (de) Zusammensetzung zur intestinalen verabreichung
Kusakabe et al. Occurrence of a novel enzyme, L-lysine oxidase with antitumor activity in culture extract of Trichoderma viride
Damink et al. Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule
ATE315084T1 (de) Herstellung von rhpbgd
CN103146789A (zh) 一种胶原蛋白的制备方法
Kaczmarek et al. Inhibitors of polyamine biosynthesis block tumor necrosis factor-induced activation of macrophages
ATE487390T1 (de) Proteinzusammensetzung zur behandlung eines physiologisch bedingten, klinisch unauffälligen proteinmehrbedarfs
PT1296675E (pt) Composicoes a base de aminoacidos apropriadas para o tratamento da insuficienciacardiaca
Oh et al. Hypolipidemic and antiinflammatory effects of fermented Maillard reaction products by Lactobacillus fermentum H9 in an animal model
Borsook Enzymatic syntheses of peptide bonds
JP2002284668A (ja) クスミの予防・治療剤
JP2004331564A (ja) 皮膚コラーゲン産生促進剤
Millán What can we learn about the neural functions of TNAP from studies on other organs and tissues?